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Multi-functionalised graphene nanoflakes as tumour-targeting 
theranostic drug-delivery vehicles 
Jennifer Lamb,a Eliane Fischer,a Martin Rosillo-Lopez,b Christoph G. Salzmannb and Jason P. 
Hollanda* 
Graphene nanoflakes (GNFs) consist of a graphene sheet approximately 30 nm in diameter with a pristine aromatic system 
and an edge terminated with carboxylic acid groups. Their high water solubility and relative ease of functionalisation using 
carboxylate chemistry means that GNFs are potential scaffolds for the synthesis of theranostic agents. In this work, GNFs 
were multi-functionalised with derivatives of (i) a peptide-based Glu-NH-C(O)-NH-Lys ligand that binds prostate-specific 
membrane antigen (PSMA), (ii) a potent anti-mitotic drug (R)-ispinesib, (iii) the chelate desferrioxamine B (DFO), and (iv) an 
albumin-binding tag reported to extend pharmacokinetic half-life in vivo. Subsequent 68Ga radiochemistry and experiments 
in vitro and in vivo were used to evaluate the performance of GNFs in theranostic drug design. Efficient 68Ga-radiolabelling 
was achieved and the particle-loading of (R)-ispinesib and Glu-NH-C(O)-NH-Lys was confirmed using cellular assays. Using 
dose-response curves and FACS analysis it was shown that GNFs loaded with (R)-ispinesib inhibited the kinesin spindle 
protein (KSP) and induced G2/M-phase cell cycle arrest. Cellular uptake and blocking experiments demonstrated that GNFs 
functionalised with the Glu-NH-C(O)-NH-Lys ligand showed specificity toward PSMA expresseing cells (LNCaP). The 
distribution profile and excretion rates of 68Ga-radiolabelled GNFs in athymic nude mice was evaluted using time-activity 
curves derived from dynamic positron-emission tomography (PET). Image analysis indicated that GNFs have low 
accumulation and retention in background tissue, with rapid renal clearance. In summary, our study shows that GNFs are 
suitable candidates for use in theranostic drug design. 
 
Introduction 
The underlying concept of a ‘theranostic’ drug is to combine 
chemotherapeutic and diagnostic capabilities in a single 
compound. Such an agent would allow the distribution of the 
drug to be tracked in real time and the dose delivered to the 
lesion to be determined accurately.1–3 In recent years, 
graphene-based nanomaterials have been studied for potential 
use in various biological applications.4–9 For instance, modified 
graphene nanomaterials and carbon nanotubes show potential 
in anti-cancer treatments, as drug delivery vehicles, and in 
diagnostic imaging.10–14 If these different applications can be 
combined, then graphene nanomaterials could be used in the 
synthesis of ‘theranostics’.15 
The covalent modification of graphene sheets and carbon 
nanotubes is chemically challenging. Disrupting the delocalised 
p-bonding network of the graphene sheet is thermodynamically 
unfavourable due to steric and electronic factors.16 Most 
reactions that lead to graphene or nanotube functionalisation 
overcome these issues by exposing the material to harsh 
reagents and conditions.17 As a result, the activation chemistry 
often forms a heterogeneous surface consisting of different 
graphene oxide (GO) and reduced graphene oxide (rGO) 
groups.18–20 Modification of the oxygen-containing functional 
groups on GOs and rGOs is relatively simple and the increased 
polarity improves water solubility. For example, Shi et al. 
modified rGO with polyethylene glycol (PEG), a tumour 
targeting vector, and a 64Cu-radiolabelled complex, creating a 
targeted positron emission tomography (PET) radiotracer.12 
While GO and rGO are promising scaffolds for drug design, 
the heterogenous chemical nature of the graphene materials is 
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an issue. Specifically, standard GO and rGO materials contain 
varying amounts of oxide, hydroxide and epoxide groups 
scattered throughout their structures. This makes it challenging 
to control the chemo- and regioselectivity of functionalisation 
reactions. In addition, heterogeneity in the starting materials 
hinders batch-to-batch reproducibility by increasing variability 
in the product.  
In an effort to circumvent some of these issues, we recently 
synthesised edge-carboxylated graphene nanoflakes (GNFs) via 
the oxidative breakdown of chemical vapour deposition (CVD) 
multi-walled carbon nanotubes.21,22 Unlike GO and rGO 
materials, GNFs consist of a single graphene sheet 
approximately 30 nm in diameter with a pristine aromatic 
system. The GNF edge is terminated with carboxylic acid groups 
that can form carboxylic anhydrides (Figure 1A).22 An atomic 
force microscopy image of GNFs spin-coated from aqueous 
dispersion onto highly oriented pyrolytic graphite is shown in 
Figure 1B. The high solubility in water, negative zeta potential,22 
and relative ease of functionalisation using carboxylate 
chemistry means that GNFs are potential platforms for the 
design of theranostic agents, where reactions can be restricted 
to the carboxylated edge.  
 
Fig. 1 (A) Chemical structure of a small GNF (not to scale). (B) Atomic force 
microscopy image of GNFs spin-coated onto highly oriented pyrolytic graphite. 
 
In this work, we used pristine GNFs to synthesise a series of 
theranostic agents for targeted drug delivery and PET imaging. 
With this in mind, GNFs were decorated with several different 
components. Desferrioxamine B (DFO) is a well-known chelate 
for Fe3+, Zr4+ and Al3+ ions (among others) but also binds gallium 
with high affinity (formation constant, logb = 28.2).23 68Ga is a 
positron emitting radionuclide suitable for PET imaging and is 
readily accessible via commercially available 68Ge/68Ga 
generators. (R)-Ispinesib is an extremely potent anti-mitotic, 
anti-cancer drug that targets the kinesin spindle protein (KSP); 
a motor protein that plays a critical role in mitosis by mediating 
centrosome separation and bipolar spindle formation.24 
Inhibiting KSP causes cell cycle arrest at the mitotic (M) phase, 
eventually leading to apoptosis.25 Alongside its potency, (R)-
ispinesib is a convenient choice of drug for GNF modification 
due to its free primary amine which lies outside of the KSP 
binding pocket and is available for chemical modification.24 An 
additional goal was to incorporate a biologically active vector 
that targets a characteristic protein on  prostate cancer cells. 
For this purpose, we selected the urea-based Glu-NH-C(O)-NH-
Lys group, which has a high affinity and specificity toward 
prostate-specific membrane antigen (PSMA). Finally, we also 
functionalised GNFs with a pharmacokinetic modifying group 
(an albumin binding tag) that alters the interaction with 
systemic proteins and can modulate distribution profiles in vivo. 
In summary, the synthesis, in vitro and in vivo evaluation of 
theranostic GNF vehicles with up to four different 
functionalities was explored. 
Experimental 
Full experimental methods and materials are reported in the 
supplementary information.  
Results and discussion 
Functionalisation of GNFs 
Four different GNF constructs (GNF-1, -2, -3 and -4, Figure 2) 
were synthesised to evaluate the use of GNFs as a platform for 
the construction of theranostic agents. GNF-1 was produced by 
pre-activating the carboxylated edge using HATU, and 
sequential conjugating to DFO via amide bond formation. The 
DFO chelate can be radiolabelled readily with 68Ga3+ ions using 
established methods, allowing the use of radiochemistry to 
determine the success of the chemical reaction.26 Radiolabelling 
(see below) confirmed that the DFO functionalisation reaction 
and the purification step were successful. With this information, 
we then used the same conjugation chemistry to functionalise 
GNFs with DFO, Glu-NH-C(O)-NH-Lys, and (R)-ispinesib to 
produce GNF-2. The free amine on all components allowed 
functionalisation via a one-pot, multi-component reaction. 
Purification was achieved on silica gel. Interestingly, when 
water is used as the mobile phase, the modified GNFs ran at the 
solvent front, allowing efficient separation from other 
compounds in the reaction mixture which were retained on 
silica. 
 
Fig. 2 Schematic structures of [68Ga]GNF-1, -2, -3, and -4. In each case, the GNFs 
are functionalised with multiple copies of each component. (A) GNF with the 
chelate DFO. (B) GNF with DFO, (R)-ispinesib, and the PSMA ligand. (C) GNF with 
DFO, (R)-ispinesib, and the PEG4-PSMA ligand spaced with a PEG4 linker. (D) GNF 
with DFO, (R)-ispinesib, PEG4-PSMA, and an albumin binding tag. 
 
GNF-3 and GNF-4 were synthesised using the same 
chemistry. We hypothesised that by creating some distance 
between the GNF and Glu-NH-C(O)-NH-Lys, PSMA binding 
would be improved, and hence, increasing the specific uptake 
in target cells (LNCaP [PSMA +ve]). Therefore, GNF-3 included a 
PEG4 linker between the GNF and the PSMA ligand. The 
synthesis of Glu-NH-C(O)-NH-Lys-NH-C(O)-PEG4-NH2 (Scheme 
S1) allowed the free amine to be used in the equivalent HATU-
mediated amide bond formation as before.  
Next, we speculated that the relatively small size, negative z 
potential, and low lipophilicity of the GNFs would cause fast 
excretion of the compounds in vivo. The structure of GNF-4 sees 
the addition of N-(4-aminobutyl)-6-(4-iodophenyl)butylamide – 
a recognised affinity tag for albumin – in an attempt to 
modulate circulation times. Antibody fragments with similar 
derivatisation have been reported to bind albumin, and in turn, 
showed increased circulation half-life in vivo.27  
Following the synthesis and isolation of the four GNF 
constructs, the zeta (z) potentials were measured. GNF-1 and 
GNF-2 exhibited similar z potentials (-36.0 ± 4.87 and -39.5 ± 
8.12 mV respectively) compared to non-modified GNFs (-37 ± 
10.2 mV, note: this measured value is consistent with previous 
reports22). GNF-3 had a decreased z potential (-60.7 ± 10.3 mV) 
consistent with the additional PEG4 ether groups causing an 
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increase in negative charge at the slipping plane. Despite also 
containing the PEG4 linker, GNF-4 displayed a less negative z 
potential (-42.3 ± 7.80 mV) which is consistent with addition of 




DFO modification allowed for efficient radiolabelling of GNF-1, 
-2, -3 and -4, using the same general procedure for each 
construct. An aliquot of stock [68Ga][Ga(H2O)6]Cl3(aq.) (~40 
MBq) was added to an aqueous solution of the functionalised 
GNFs (25 µg) buffered with NaOAc (0.2 M, pH4.4), and the 
mixtures were incubated 10 min. at 21 oC (n = 3 independent 
reactions per compound). Radiochemical reactions were 
monitored by using radioactive instant thin-layer 
chromatography (radio-iTLC) and size-exclusion 
chromatography (SEC) (Figure 3). Radiochemical conversions 
(RCCs) for the synthesis of 68Ga-labelled GNF-1, -2, -3 and -4 
were typically >97% (measured by radio-iTLC), with specific 
activities ranging from 8.7 ± 2.4 GBq mg-1 to 10.4 ± 3.0 GBq mg-
1 (Table 1). Extending reaction times and heating the mixtures 
to 70 oC did not improve the percentage of radiochemical 
conversion. Chelate-free radiolabelling of rGO with 64Cu2+ has 
been reported.28 A chelate-free approach can be beneficial as 
the addition of chelates to a nanoparticle (or other biological 
vector) can often alter the properties of the graphene, hence 
changing results in vivo.29 The intrinsic radiolabelling of the 
GNFs with 68Ga was attempted, but no labelling was observed, 
which also provided further confirmation that the DFO 
functionalisation was successful.  
By using the experimentally measured molar activity of the 
[68Ga][Ga(H2O)6]Cl3(aq.) stock solutions, radioactive titrations 
allowed the quantification of the amount of DFO loaded per unit 
mass of GNF nanoparticle. Titration experiments showed that 
the functionalised compounds GNF-1, -2, -3, and -4 contained 
similar amount of DFO (ranging from ~44 – 53 nmol DFO per mg 
GNF) indicating that the conjugation reactions proceeded with 
similar efficiency for each compound and that adding multiple 
components to the different GNF constructs did not 
compromise reaction efficiency (Table 1, Figure S1).  
 
Table 1. Characterisation data associated with [68Ga]GNF-1, -2, -3, and -4. 
 
Estimates of the lipophilicity of the samples were obtained 
by measuring distribution coefficients (logD) using standard n-
octanol / PBS (pH7.4) partition experiments (Table 1).30 As 
expected, radiolabelled compounds [68Ga]GNF-1, -2, -3 and -4, 
were found to have negative logD values in the range -1.75 to -
3.34. Functionalisation of the GNF nanoparticles with Glu-NH-
C(O)-NH-Lys and (R)-ispinesib (GNF-2) reduced the 
hydrophilicity (logD value of -2.48 ± 0.01, n = 3), which suggests 
that the lipophilic quinazolinone drug was loaded onto the 
particles. For GNF-3, the presence of the PEG4-spacer between 
the nanoparticle and the Glu-NH-C(O)-NH-Lys group increased 
the hydrophilicity (logD = -3.14 ± 0.06, n = 3). Also, as 
anticipated, loading the nanoparticles with the N-(4-
aminobutyl)-6-(4-iodophenyl)butylamide tag made construct 
GNF-4 less hydrophilic (logD = -1.75 ± 0.07, n = 3). 
Stability studies in vitro confirmed that the 68Ga-
radioactivity remained bound to the particles when incubated 
in solutions of saline (2 h), PBS (2 h) or human serum (2.5 h) at 
37 oC (Table S1, Table S2, Figure S2). 
 
Cellular studies 
To determine the presence and activity of the (R)-ispinesib and 
Glu-NH-C(O)-NH-Lys on GNF-2, -3, and -4, a range of different 
cellular assays were performed. The PSMA expressing LNCaP 
cell line was used in all cell assays with PC-3 (PSMA negative) 
cells used in appropriate control experiments. 
 
Anti-proliferation assays. Cellular anti-proliferation assays 
(MTT) were used to measure growth inhibition induced by 
incubation of LNCaP cells with the different GNF constructs at 
varying concentrations. In positive control experiments, a 
classic biphasic profile was observed after incubating cells for 
48 h with (R)-ispinesib (Figure S3).24 Analysis of the growth 
curves gave two distinct values for the growth-inhibition (GI50) 
values with a GI50(1) of 3.32 ± 2.31 µM and a second GI50(2) 
value of 0.7 ± 26.7 nM. At high concentrations, the compound 
is cytotoxic to cells which corresponds to the first GI50(1) value. 
At lower concentrations, a plateau region is observed in which 
the cells are cytostatic with cell cycle arrest occurring in the 
G2/M phase. As the drug concentration decreases into the 
nanomolar range, a second step is observed corresponding to 
the GI50(2) value, followed by recovery of cellular proliferation 
to control levels.  
To determine the success of the functionalisation of the GNF 
with (R)-ispinesib, we exposed cells to GNF-2 to observe the 
effect on cellular proliferation. GNF-2 exhibited a similar 
biphasic profile to the drug alone, indicating that the nanoflake 
was successfully modified and was also a potent inhibitor of 
cellular growth and proliferation (Figure 4A). To determine if 
further functionalisation of a graphene nanoflake with PEG4 
linkers and additional pharmacokinetic modifying groups (the 
albumin binder) had an impact on the anti-proliferative activity, 
equivalent MTT assays were conducted using GNF-3 and GNF-4 
(Figures 4B and 4C, respectively). Again, characteristic biphasic 
profiles were observed which suggested more extensive 
derivatisation of the nanoflakes did not alter the drug loading 
capacity or biological activity. Similar to (R)-ispinesib, two 
separate growth inhibition values could be extracted from the 
biphasic curves giving values centred in the micro- (GI50(1) / µg 
mL-1) and nano- (GI50(2) / ng mL-1) mass concentration ranges 
for GNF-2, -3 and -4 (Table 2). It is worth noting that anti-
proliferation assays with (R)-ispinesib alone require the use of 
DMSO to solubilise the compound. The high aqueous solubility 
of GNFs meant that DMSO was unnecessary when using the 
GNF constructs. This fact provides additional support for 
development of nanoflakes as potential drug-delivery vehicles. 
 
Fig. 4 Cellular anti-proliferation (MTT) curves showing the response of LNCaP 
(PSMA +ve) cells to treatment with (A) GNF-2, (B) GNF-3, and (C) GNF-4. In each 
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plot, the black data points correspond to treatment of the LNCaP cells with the 
native (non-functionalised) GNF in the same formulation as the active compounds. 
 
Table 2. GI50 values of GNF-2, -3 and -4 extracted from the biphasic profiles 
observed in the anti-cellular proliferation assays. 
 
Cell cycle analysis. Although the biphasic profile in MTT assays 
is a characteristic feature of KSP inhibition using (R)-ispinesib, 
the mechanism of cell cycle inhibition was confirmed by using 
fluorescence-assisted cellular sorting (FACS). After treatment of 
LNCaP cells for 36 h with two different concentrations of GNF 
constructs, (12 ng mL-1 and 120 ng mL-1 of GNF, GNF-2, -3 and -
4) the DNA content was measured by staining cells with 
propidium iodide (PI). FACS analysis showed that samples 
treated with GNF-2, -3 or -4 exhibited an increase in the 
proportion of cells in the G2/M phase compared with either 
vehicle-treated cells or cells treated with GNF alone (Figure 5, 
Table 3). For example, cells treated with 120 ng mL-1 GNF-2 
showed an increased number of cells in the G2/M phase (~87%) 
in comparison to control samples which gave relative G2/M 
phase populations of 9% in untreated samples, and 7% in GNF 
treated samples. Interestingly, the proportion of cells in the 
G2/M phase was also seen by FACS to be concentration 
dependent. For example, for LNCaP cells treated with a lower 
concentration of GNF-2 (12 ng mL-1), the percentage of cells in 
G2/M phase reduced to 29%. A similar trend was observed for 
GNF-3 and GNF-4. This observation is consistent with the 
biphasic curve seen in the anti-proliferation assay. Collectively, 
the anti-proliferation assays and FACS data support the 
conclusion that GNF-2, -3 and -4 were successfully 
functionalised with (R)-ispinesib, and that the drug remained 
active toward KSP inhibition. 
 
Fig. 5 Cell cycle analysis derived from FACS analysis with concentrations (A) 120 ng 
mL-1 and (B) 12 ng mL-1 of compounds. 2N refers to cells in the G0/G1 phase whilst 
4N refers to cells in the G2/M phase. 
 
Table 3. Percentage of cells in the G0/G1, S and G2/M phase. Data extracted from 
FACS cell cycle analysis using the Flowjo software (Watson model). 
 
Confocal Microscopy. As a final confirmation that the 
mechanism of G2/M phase arrest was associated with KSP 
inhibition, confocal microscopy images of cells that were 
incubated with GNF, GNF-2, -3 or -4 (and controls) were 
obtained (Figure 6). Untreated samples and slides treated with 
the control GNF sample showed predominantly cells in 
interphase region of the cell cycle with DNA (stained with 
Hoechst 33342) concentrated in a well-defined nucleus. These 
control experiments showed no evidence of G2/M phase arrest 
and confirmed the results from the FACS which showed that 
GNF particles (or the vehicle) alone do not interfere with the 
cell. In comparison, cells treated with GNF-2, -3 or -4 exhibited 
a characteristic punctate pattern of DNA distributed throughout 
the cell with no defined nucleus. The phenotype observed in 
these confocal cellular fluorescence microscopy data is 
consistent with previous reports on the mechanism of action of 
(R)-ispinesib in various cancer cells.24,31,32  
 
Fig. 6 Confocal microscopy images showing the effects of treatment of LNCaP cells 
with GNF, GNF-2, GNF-3, GNF-4. Microtubules stained with Alexa Flour 568 (red) 
and DNA stained with Hoechst 33342 (blue). (Inset) Scale bars correspond to 10 
µm. 
 
Cellular association assays. PSMA (also known as glutamate 
carboxypeptidase II or N-acetyl-L-aspartyl-L-glutamate 
peptidase I) is a membrane-bound zinc metalloenzyme which is 
upregulated in many prostate cancer cells.33 The Glu-NH-C(O)-
NH-Lys group is a well-documented inhibitor of PSMA and many 
urea-based, small-molecule radiotracers have tested in vivo and 
in human trials.26,34–37 To determine if GNF-2, -3 and -4 were 
successfully functionalised with the PSMA binding ligand, 
radioactive cellular binding and blocking assays were conducted 
using LNCaP cells (PSMA +ve)(Figure 7A). [68Ga]GNF-2, 
[68Ga]GNF-3 and [68Ga]GNF-4 showed an increased uptake in 
LNCaP cells compared with [68Ga]GNF-1. PC-3 cells (PMSA –ve) 
were also used as a negative control cell line. A statistically 
significant decrease in cellular associated activity was observed 
in PC-3 cells compared with the activity accumulation in the 
LNCaP cells for [68Ga]GNF-2 (p≤0.01), [68Ga]GNF-3 (p≤0.001) 
and [68Ga]GNF-4 (p≤0.0001). These results were encouraging 
and suggested that functionalisation of GNFs with tumour-
targeting groups was successful. However, a comparison 
between the LNCaP and PC-3 cell lines showed that the GNF 
constructs also exhibit non-specific binding which accounted for 
up to ~50% of the cell-associated activity. For instance, this non-
specific binding component can be seen in the relative amount 
of [68Ga]GNF-1 versus the ‘targeted’ GNF constructs. Non-
specific binding is difficult to circumvent and is likely due to the 
interaction of the GNFs with cellular proteins, a phenomenon 
that has been observed for other nanographene materials.38,39 
We hypothesised that increasing the distance between the 
GNFs and the Glu-NH-C(O)-NH-Lys targeting vector using a PEG4 
linker may increase the cellular uptake and specificity for LNCaP 
cells. However, no difference was observed between the cell-
associated uptake of [68Ga]GNF-2 and that [68Ga]GNF-3 (Figure 
7A). It is possible that the short PEG4 chain is insufficient to shift 
the uptake mechanism away from non-specific accumulation 
and toward specific PSMA-mediated binding. Also of note, the 
slightly higher cell-associated activity observed for [68Ga]GNF-4 
in LNCaP cells was simply attributed to an increased non-specific 
uptake which was also seen in the data using PC-3 cells. 
 
Fig. 7 (A) Cellular binding assay of [68Ga]GNF-1-4 with the LNCaP (PSMA +ve) and 
PC-3 (PSMA –ve) cell lines. Data given as the percentage of activity bound 
normalised per 1 mg mL-1 of total protein. All cell media contained 0.1% azide and 
protein content was measured using a BCA assay. For the LNCaP cell line: 
[68Ga]GNF-1 vs. [68Ga]GNF-2, p≤0.01; [68Ga]GNF-1 vs. [68Ga]GNF-3 p≤0.001; 
[68Ga]GNF-1 vs. [68Ga]GNF-4, p≤0.0001.  Comparison of cell lines: PC-3 vs. LNCaP 
[68Ga]GNF-2, p≤0.01; [68Ga]GNF-3, p≤0.001; and [68Ga]GNF-4, p≤0.0001. (B) 
Blocking assay with the LNCaP (PSMA +ve) cell line pre-treated with free Glu-NH-
C(O)-NH-Lys ligand (5 µM) before addition of radiotracers. Note: Student’s t-test 
analysis: ns = not significant, * = P-value < 0.05, ** = P-value < 0.01, *** = P-value 
< 0.001. 
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Cellular blocking assays. The cellular association assays 
suggested that a two-state mechanism of cellular binding, 
involving both specific and non-specific accumulation, was 
operating for the targeted constructs GNF-2, -3, and -4. 
Therefore, to provide further confirmation of the presence of 
the Glu-NH-C(O)-NH-Lys group on GNF-2, -3, and -4, and to 
evaluate the fraction of specific binding observed using the 
LNCaP cells, blocking studies were performed. LNCaP cells were 
first incubated with ~1000-fold excess of the free Glu-NH-C(O)-
NH-Lys ligand (5 µM) for 1 h prior to the addition of radiotracers 
(Figure 7B). The blocking studies confirmed that the 
radioactivity associated with the LNCaP cells could be reduced 
by 32 ± 9% for [68Ga]GNF-2, 76 ± 36% for [68Ga]GNF-3 and 37 ± 
10% for [68Ga]GNF-4 (Figure 7B). Whilst the relatively high 
fraction of non-specific binding indicated that more work is 
required to optimise these constructs, the blocking experiments 
confirmed that GNFs can be targeted toward specific 
biomarkers on cancer cells. 
 
In vivo studies 
Next, to gauge the potential of using nanoflakes in vivo, we 
performed dynamic PET imaging to measure the 
pharmacokinetic (PK) distribution and excretion profiles of 
[68Ga]GNF-3 and [68Ga]GNF-4 in a limited number of athymic 
nude mice bearing subcutaneous LNCaP tumours (n ≥ 3 mice / 
compound). The main goal was to measure time-activity curves 
to obtain a baseline PK profile of GNFs, and to evaluate if 
functionalisation of the GNF constructs with an albumin binding 
tag could modulate blood pool concentrations, circulation times 
and excretion pathways.  
Pilot PET imaging experiments indicated that the small size 
and high hydrophilicity of the [68Ga]GNF-3 and [68Ga]GNF-4 
facilitated rapid clearance from the blood pool by a renal 
excretion pathway and  elimination through the bladder (Figure 
8). The observation that [68Ga]GNF-3 and [68Ga]GNF-4 are 
cleared through the kidneys is an interesting finding that may 
help minimise radiation burden to background tissues and 
facilitate further optimisation of radiotracers based on GNFs. 
Time-activity curves (TACs) showed [68Ga]GNF-3 was essentially 
first-pass extracted from the blood pool by the kidneys. Peak 
uptake in the kidney reached 38±4 %ID cm-3 within in the first 
two minutes post-administration. Concordantly, accumulation 
of 68Ga-radioactivity in the bladder increased immediately after 
injection confirming that the [68Ga]GNF-3 particles are not 
retained in the kidney (Figures 8B and S4A). In contrast, the 
peak in radioactivity in the kidneys for [68Ga]GNF-4 occurred 
between 4 – 6 minutes post-administration with a similar time 
delay observed before activity was seen to accumulate in the 
bladder (Figures 8C and S4B). For both [68Ga]GNF-3 and 
[68Ga]GNF-4, blood pool activity (as measured by drawing 
volumes of interest over the left ventricle of the heart) showed 
a peak in the first frame after bolus injection of the radiotracer, 
and a rapid decrease over the imaging time window. In 
comparison to [68Ga]GNF-3, the slight delay in extraction of the 
[68Ga]GNF-4 activity from the blood pool by the kidney, gave a 
higher blood pool peak activity of 48 ± 5 %ID cm-3. Kinetic 
analysis of the TACs found that the effective half-life of 
[68Ga]GNF-3 in the blood pool (heart) was 3.85 ± 0.35 min. 
whereas for [68Ga]GNF-4  the half-life increased to 5.22 ± 0.61 
min. (p < 0.05). These TAC data indicate that modification of the 
GNF particles with the albumin binding tag has a small but 
significant effect on prolonging the circulation time and 
reducing the elimination rate of [68Ga]GNF-4. 
 
Fig. 8 PET images recorded in mice bearing LNCaP tumours, T = tumour. A) 2 h 
coronal PET image recorded following injection with [68Ga]GNF-4. TACs plotted 
with data extracted from 30 min. dynamic PET analysis (15x2 min. scans) with 
injection of B) [68Ga]GNF-3 (n = 3) and C) [68Ga]GNF-4 (n = 4) at t = 2 min. VOI 
analysis was performed using VivoQuant™. 
 
For both [68Ga]GNF-3 and [68Ga]GNF-4, tumour-associated 
radioactivity was found to be low and non-specific. The TAC 
profiles of VOIs drawn over the tumours showed that the PK 
profile followed the same trend as the blood pool, indicating 
that the constructs do not show specific accumulation in the 
tumours on the time scale of the experiment. Factors leading to 
this lack of specific tumour uptake include the relatively high 
component of non-specific binding found for GNFs on LNCaP 
cells, the rapid excretion profile, and potentially, a reduced 
access or affinity of the Glu-NH-C(O)-NH-Lys binding ligand for 
the PSMA target when bound to the GNF particles. In spite of 
the absence of tumour uptake, the PET images provide valuable 
information which will aid further optimisation of the GNFs as 
potential drug delivery vehicles and theranostic agents. In 
particular, modification of the particles with higher affinity 
albumin tags or an increased number of tags per particle may 
increase circulation times, and more work on improving the 
cellular binding profile will likely allow increased cellular uptake 
and specificity. 
Conclusions 
GNFs were used as design scaffolds for the synthesis of targeted 
theranostic agents. Multi-functionalised GNFs can be prepared 
with a diverse array of compounds including metal-binding 
chelates, tumour-targeting ligands, cytotoxic drugs and 
pharmacokinetic modification groups. Derivatisation of GNFs 
with the potent drug molecule (R)-ispinesib gave constructs that 
remained pharmacologically active, and cellular assays 
confirmed that the mode of action was consistent with mitotic 
phase arrest induced by KSP motor protein inhibition. An 
advantage of using GNFs as a drug carrier was that it helped to 
solubilise (R)-ispinesib in water. In addition, GNF particles 
functionalised with the Glu-NH-C(O)-NH-Lys group exhibited 
enhanced cellular uptake. Although a significant fraction of 
cellular association was assigned to non-specific interactions, it 
was found that targeted GNFs showed specificity toward PSMA 
expressing cells. Dynamic PET imaging found that functionalised 
GNFs have rapid blood pool clearance and renal excretion, but 
experiments also demonstrated that functionalising with an 
albumin-binding tag resulted in a significant modulation of the 
pharmacokinetic profile. Further optimisation is required to 
enhance the uptake kinetics and distribution in vivo but our 
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study supports the conclusion that GNFs are a highly versatile 
platform for theranostic drug development. 
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Table 1. Characterisation data associated with [68Ga]GNF-1, -2, -3 and -4. 
 
 [68Ga]GNF-1 [68Ga]GNF-2 [68Ga]GNF-3 [68Ga]GNF-4 
RCC 
/ % 
99.1±0.7 98.6±0.2 97.4±0.6 97.3±0.4 
Specific Activity 
/ GBq mg-1 
9.08±2.59 8.79±0.4 10.41±2.98 8.7±2.44 
Mole of DFO per mass of 
GNF / nmol mg-1 
46.1±13.1 44.6±2.26 52.8±15.1 44.4±12.4 
logD value -3.34±0.02 -2.48±0.01 -3.14±0.06 -1.75±0.07 






Table 2. GI50 values of GNF-2, -3, and -4 extracted from the biphasic profiles observed in the anti-proliferation assays. 
 
GNF-2 GNF-3 GNF-4 
Log(GI50(1)/mg mL-1) -1.11±0.41 -0.63±0.50 -1.02±0.18 
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  Cells associated with each cell cycle phase / % 
Sample  Mass 
concentration 
/ ng mL-1 
G0/G1 S G2/M 
Vehicle  N/A 74.1 15.8 8.97 
GNF 120 71.2 10.6 7.24 
12 69.2 11.6 10.2 
GNF-2  120 4.92 5.21 87.3 
12 38.2 9.51 29.3 
GNF-3 120 4.15 4.06 89.6 
12 4.43 10.8 78.7 
GNF-4 120 5.79 6.49 77.6 
12 36.4 12.5 36.7 
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Figure 8 
 
 
